Sino Biopharmaceutical Limited (1177.HK)

2.700 -0.110 (-3.91%) At close: 04:08PM HKT

Sino Biopharmaceutical Limited

Unit 09, Office Tower
41st Floor, Room 4109 Convention Plaza 1 Harbour Road
Wan Chai
Hong Kong
852 2802 9886
https://www.sinobiopharm.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 25,806

Key executives

Name	Title	Pay	Exercised	Year born
Ms. Y. Y. Tse	Executive Chairwoman of the Board	42.84M	N/A	1992
Ms. Cheung Ling Cheng	Executive Vice Chairwoman of the Board	38M	N/A	1964
Ms. Mingqin Li	Senior VP & Executive Director	1.3M	N/A	1959
Mr. Zhoushan Tian	Executive Director	2.02M	N/A	1964
Mr. Hsin Tse	Senior VP & Executive Director	6.51M	N/A	1970
Mr. Eric S. Y. Tse	CEO & Executive Director	24.94M	N/A	1996
Mr. Ping Tse	Founder & Senior Executive Vice Chairman	45.28M	N/A	1952
Ms. Chun Ling Li	Chief Financial Officer	N/A	N/A	1972
Sean Chen	Chief Strategy Officer	N/A	N/A	N/A
Orphanides George	Chief Scientific Advisor of invoX	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in HKD.

Description

Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines, including anlotinib hydrochloride capsules under Focus V brand, penpulimab injection under Annike brand, efbemalenograstin alfa injection under Yilishu brand, pomalidomide capsules under Anyue brand, bevacizumab injection under Anbeisi brand, rituximab injection under Delituo brand, and trastuzumab for injection under Saituo brand; liver disease medications, such as magnesium isoglycyrrhizinate injection under Tianqing Ganmei brand and entecavir dispersible tablets under Runzhong brand; and respiratory system medicines comprising budesonide suspension for inhalation under Tianqing suchang brand and colistimethate sodium for injection under Tianyun brand. It also provides surgery/analgesia medicines, including flurbiprofen cataplasms under the brand Zepolas, limaprost tablets under the brand Kailitong, and recombinant human coagulation factor VIII for injection under the brand Anhengji; cardio-cerebral vascular medicines, such as irbesartan and hydrochlorothiazide tablets under the brand Yilunping and beraprost sodium tablets under the brand Kaina; and biosimilar medicines comprising adalimumab solution for injection under the brand Taibowei. In addition, the company develops oncology drugs, include benmelstobart, D-1553, TQ-B3139, and TQ-B3101; liver disease drugs, such as Lanifibranor and TQA2225/AP025; respiratory system drugs comprising TDI01, TQC2731, TCR1672, TQC3721, and TQH2722; and surgery/analgesia drugs, including PL-5, an antimicrobial peptide. Further, it is involved in the long-term investments; and healthcare and hospital business. The company was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong.

Corporate governance

Sino Biopharmaceutical Limited’s ISS governance QualityScore as of 29 April 2024 is 7. The pillar scores are Audit: 4; Board: 2; Shareholder rights: 7; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.